Literature DB >> 14669947

HLA and H2 class II transgenic mouse models to study susceptibility and protection in autoimmune thyroid disease.

Yi-Chi M Kong1, Jeffrey C Flynn, Qiang Wan, Chella S David.   

Abstract

Using single H2 and HLA class II transgenic mice, in the absence of endogenous H2 class II molecules, we have studied the permissiveness of class II molecules for experimental autoimmune thyroiditis (EAT). Resistant strains expressing susceptible class II molecules, H2Ak or HLA-DR3, developed EAT, clearly demonstrating the importance of class II gene inheritance. Polymorphism for HLA-DRB1 was observed, as DR3, but not DR2 or DR4, molecules were permissive for EAT induction with either mouse (m) or human (h) thyroglobulin (Tg). HLA-DQ polymorphism was also detectable, as hTg-induced EAT developed in DQ8+, but not DQ6+, mice. Class II gene interactions leading to reduced EAT severity were observed in H2 transgenic mice, when H2E transgene was expressed in H2A+ mice or H2A molecules were introduced into our novel H2A- E+ transgenic model. Similarly, in DR3+ mice, only the DQ8 transgene reduced EAT severity, depending on both background genes (C57BL/10 or NOD) and Tg species. Based on computer-predicted, class II-binding motifs, potential pathogenic Tg peptides, either unique to hTg (H2A- E+ model) or shared between mTg and hTg (HLA-DR3+ model), were identified. We have also developed a Graves' disease model by immunizing DR3+ mice with TSH receptor DNA. Thus, transgenic models are excellent tools to study human autoimmune thyroid diseases in the context of murine EAT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14669947     DOI: 10.1080/08916930310001603028

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  8 in total

1.  Fine epitope mapping within the pathogenic thyroglobulin peptide 2340-2359: minimal epitopes retaining antigenicity across various MHC haplotypes are not necessarily immunogenic.

Authors:  Aikaterini Hatzioannou; Maria Alevizaki; George Carayanniotis; Peggy Lymberi
Journal:  Immunology       Date:  2012-03       Impact factor: 7.397

2.  Efficacy of HLA-DRB1∗03:01 and H2E transgenic mouse strains to correlate pathogenic thyroglobulin epitopes for autoimmune thyroiditis.

Authors:  Yi-chi M Kong; Nicholas K Brown; Jeffrey C Flynn; Daniel J McCormick; Vladimir Brusic; Gerald P Morris; Chella S David
Journal:  J Autoimmun       Date:  2011-06-17       Impact factor: 7.094

Review 3.  Delineating the autoimmune mechanisms in Graves' disease.

Authors:  Syed A Morshed; Rauf Latif; Terry F Davies
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

4.  H2E-derived Ealpha52-68 peptide presented by H2Ab interferes with clonal deletion of autoreactive T cells in autoimmune thyroiditis.

Authors:  Nicholas K Brown; Daniel J McCormick; Chella S David; Yi-chi M Kong
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

5.  A novel H2A-E+ transgenic model susceptible to human but not mouse thyroglobulin-induced autoimmune thyroiditis: identification of mouse pathogenic epitopes.

Authors:  Nicholas K Brown; Daniel J McCormick; Vladimir Brusic; Chella S David; Yi-Chi M Kong
Journal:  Cell Immunol       Date:  2008-04-14       Impact factor: 4.868

Review 6.  Autoimmune thyroiditis: a model uniquely suited to probe regulatory T cell function.

Authors:  Yi-Chi M Kong; Gerald P Morris; Nicholas K Brown; Yan Yan; Jeffrey C Flynn; Chella S David
Journal:  J Autoimmun       Date:  2009-10-12       Impact factor: 7.094

7.  Both positive and negative effects on immune responses by expression of a second class II MHC molecule.

Authors:  Peggy P Ni; Yaming Wang; Paul M Allen
Journal:  Mol Immunol       Date:  2014-07-10       Impact factor: 4.407

8.  Pathogenicity of a human thyroglobulin peptide (2340-2359) in mice with high or low genetic susceptibility to thyroiditis.

Authors:  Aikaterini Hatzioannou; Elisavet Liakata; Evangelos Karras; Apollon Thrasyvoulides; Maria Alevizaki; Peggy Lymberi
Journal:  Immunology       Date:  2007-06-29       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.